Meet The Winemaker Changing The Face Of Sonoma Wine
Jesse Katz walking in his Farrow Ranch vineyard
For decades, Napa Valley has been synonymous with pedigreed Cabernet Sauvignon and Bordeaux-style blends, but the spotlight is beginning to shift westward—toward Sonoma. Sonoma is rightly celebrated for its exquisite Pinot Noir and Chardonnay wines but now its Bordeaux varietals are earning a seat at the table—and wine lovers should take note. A growing number of producers are earning critical acclaim, including rare 100-point scores that were once almost exclusively the domain of Napa's elite, and one of the key figures driving this evolution is winemaker Jesse Katz of Aperture Cellars. Kyle Connaughton, chef and owner of Sonoma's three-Michelin-starred SingleThread restaurant, credits Katz with helping to raise the region's profile: 'In such a short time, Jesse has raised the bar so incredibly high in our region. His wines stand at the top of their class compared to great Old World counterparts, while simultaneously being innovative, provocative, and approachable. He is ushering in a new era of what's possible in California winemaking, and as a chef, I'm always incredibly excited and inspired to cook for his wines.'
Katz is not alone. Wineries like Vérité, which has received perfect scores for red blends that blur the line between Sonoma and Bordeaux, as well as Skipstone, Stonestreet, and Peter Michael have contributed to Sonoma's increasing stature in the wine world. The numbers don't lie; according to Wine-Searcher, the number of Sonoma County wines receiving 95 points or higher from top critics has more than doubled over the past decade.
Tasting room at Aperture Cellars in Sonoma
Katz, whose résumé includes tenure at the revered Napa estate Screaming Eagle, brings obsessive precision and artistry to his winemaking and viticulture and the results reflect his focus. Indeed, Katz is the first and only winemaker to ever earn a 100 point score for wine made in Sonoma's Alexander Valley—from six different critics no less. And, he's earned more perfect scores than any Sonoma winemaker to date.
While critics' scores aren't the sole measure of quality, they are an important barometer of excellence. And in this case, they signal a notable shift: Sonoma is no longer just Napa's country cousin. It is emerging as a destination for world-class wines and deserving of equal—if not greater—attention from collectors and connoisseurs alike.
After so much success in Napa, it's worth asking why Katz ventured into Sonoma. For him, the decision was a no-brainer: greater opportunity and diversity. 'There is so much potential in Sonoma,' explains Katz, 'finding the next great site is still very much a possibility. The best sites in Napa have already been discovered. And for someone like me who wasn't born into this industry or into wealth the barrier to entry in Napa was almost unachievable. It was hard enough even in Sonoma.'
Rolling hills of Aperture's Farrow Ranch in Sonoma's Alexander Valley
This sprawling county (Sonoma is 1,575 square miles compared to Napa's 789 square miles) runs from the Pacific to the Mayacamas Mountains and is home to every kind of microclimate imaginable. It has more soil diversity than the entire nation of France and is composed of a constellation of quirky small towns populated by a mix of hippies and farmers. Only a few decades ago, Sonoma's now buzzy Healdsburg Square was a Hell's Angels biker hotspot (some of whom used the square's fountain to bathe). Today, the bikers are gone, replaced by Michelin-starred restaurants, five-star hotels, and boutique shops. In keeping with this evolution, the winemaking has become more focused; consider that Alexander Valley is about to debut its first-ever sub ava, Pocket Peak, which will represent some of the region's most exquisite vineyard offerings. Not surprisingly, Katz's most prized vineyard, Farrow Ranch, sits right in the heart of it.
'It's a magical, unicorn of a site,' explains Katz, 'One of the best I've worked with in my career.' It was at Farrow Ranch that Katz discovered an intriguing block of old vine Malbec, (the source of his now-famous Devil Proof bottling, which received the first-ever 100-point score for a Malbec in US history). That success inspired Katz even more. 'For the last decade of my life, I've been focused on soils and identifying unique pockets where I can unlock their potential. One of Aperture's great successes has been our ability to find sites others have overlooked and redesign, replant and farm them in a completely new way.'
Farrow Ranch is a bowl-shaped paradise where Katz cultivates Bordeaux varietals on a range of different soil types, at different elevations and oriented in all directions. This amazing tapestry of vineyard variety gives Katz and his team remarkable flexibility at the blending table, enabling them to craft deeply complex wines. 'It's a site that hasn't even hit its stride yet,' he says. 'We've planted 17 new acres and have another phase planned for 2026.'
Sonoma's rise isn't about one winemaker making 100-point wines; it's more of a team effort with everyone sharing in each other's expertise across all aspects of winemaking and hospitality. On any given day one might spot a local chef wandering Aperture's vineyards on a foraging mission. Not long ago, Katz shared some of his decommissioned wine with local chef Dustin Valette (owner of The Matheson) who then used it to craft a wine-infused mustard. And, Christopher Jackson, proprietor of Jackson Family Wines, is working with Katz on a special winemaking project called Prophet and Poet; the 2021 releases just made their debut.
Katz owns Aperture in partnership with his father, acclaimed photographer Andy Katz—and the winery name couldn't be more fitting. In photography, 'aperture' refers to the control of light and focus, and that's exactly what Katz is bringing to Sonoma: a sharp focus and a spotlight on the region's viticultural brilliance. If you want in on the ground floor, you'd better make your way to Sonoma soon.
Aperture Collage: Katz's newest and most groundbreaking wine, these two bottlings feature the best of the best hand-selected fruit from across a portfolio of 200 acres. 2021 Cabernet Sauvignon ($425) and a 2022 Sauvignon Blanc ($125).
Aperture Site Series is a collection of single-vineyard wines, each sourced from one meticulously chosen vineyard site in Sonoma County
2022 Aperture Oliver Ranch Cabernet Sauvignon | $150
2022 Aperture Del Rio Vineyard Cabernet Sauvignon | $150
2022 Aperture SJ Ranch Vineyard Cabernet Sauvignon | $150
2022 Aperture Proterra | $175
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
35 minutes ago
- Yahoo
2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts
These biotech companies have several catalysts ahead -- and in the past have soared on good news. They both offer innovative candidates that could result in game-changing treatments for patients. 10 stocks we like better than Viking Therapeutics › If you're looking to add growth to your portfolio, biotech stocks can be a great choice. Exciting research is happening in these companies' labs, and in some cases, game-changing treatment candidates are approaching important milestones or even going over the finish line. As an investor in these companies, you can benefit as they report positive clinical trial news, score a regulatory approval, or start generating product revenue. Wall Street considers two candidates extremely compelling right now, with forecasts for potential gains of more than 80% and 200% in the coming 12 months. One of these players is working in the high-growth area of weight loss drugs, and the other candidate showed its strengths by winning the world's first-ever approval of a product based on CRISPR gene editing. Let's check out these two biotech stocks to buy before they skyrocket. Viking Therapeutics (NASDAQ: VKTX) soared early last year when it reported strong data from the phase 2 trial of its weight loss candidate, VK2735, but the stock has since given back those gains and is trading closer to the level it was at prior to that data announcement. Since, the company has continued to advance VK2735 in injectable form and a version in pill form, and demand for these sorts of drugs remains high -- these are two reasons to believe that Viking has the potential to take off again. And catalysts may be on the horizon. The drug works in a manner similar to Eli Lilly's blockbuster tirzepatide, sold under the names Mounjaro and Zepbound. These drugs interact with hormones involved in digestion and have helped people quickly and safely lose weight. Viking is beginning the phase 3 trial for injectable VK2735 in the second quarter and expects data from its phase 2 trial of the pill version in the second half. Any data announcements could result in big moves for the stock, as there is plenty of room for a new company to enter the weight loss drug market -- one forecast to approach $100 billion in a few years. Wall Street is optimistic about Viking's prospects, with the average price forecast predicting an increase of about 240% in the stock price from today's level. Of course, Viking depends heavily on the outcome of these trials, so some risk is involved -- but data have been strong, so growth investors may want to get in on Viking now to potentially post a big win later. CRISPR Therapeutics (NASDAQ: CRSP) stock surged in the year leading up to a major milestone: its first product approval. But since last year's launch of Casgevy, a gene-editing treatment for blood disorders, the stock has been on the decline. Sometimes, investors buy a stock well before the company wins approval or launches a product, then lock in gains after the good news lands -- and I think this is what's happened here. But what this does is offer us a chance to get in at a very good price on a promising company that could deliver fantastic news down the road. Casgevy, as a gene-editing treatment, requires a longer time to roll out than a pill or injection, as it includes several steps that happen over a period of months. The company recently said new patient initiations should increase "significantly" this year -- so there's reason to be optimistic about revenue growth ahead. CRISPR Therapeutics also recently reported positive phase 1 data for a gene editing candidate addressing the problem of high cholesterol. And the company expects to report data soon from a phase 1 trial of a candidate targeting patients with elevated levels of lipoprotein(a) -- a risk factor for cardiovascular events. These could represent huge markets for CRISPR Therapeutics if the candidates reach the finish line, and in the meantime, any potential positive news could boost the stock. The company also expects other trial updates in candidates for oncology and autoimmune diseases this year -- so this biotech's calendar is full of possible catalysts. Wall Street's average price forecast calls for an 84% gain for CRISPR Therapeutics from today's price -- if all goes well in clinical trials and Casgevy starts to show revenue growth, now could represent a golden buying opportunity for growth investors. Before you buy stock in Viking Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Viking Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $664,089!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $881,731!* Now, it's worth noting Stock Advisor's total average return is 994% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Adria Cimino has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends CRISPR Therapeutics. The Motley Fool recommends Viking Therapeutics. The Motley Fool has a disclosure policy. 2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
38 minutes ago
- Yahoo
Dan Ives Says Market Is 'Massively Underestimating' This AI Play, Urges Investors To Look Beyong Mag 7
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Dan Ives' new artificial intelligence exchange-traded fund (ETF) holds securities beyond the Magnificent 7 stocks, as he believes in looking past valuations for investments in the technology sector. What Happened: The Dan IVES Wedbush AI Revolution ETF (NYSE:IVES), managed by the Wedbush analyst, started trading on June 4, earlier this month. Ives boasts of the fund by saying that it just doesn't have the top four, five Magnificent 7 names, but stocks which investors wouldn't even thematically consider as an AI name today. "I believe the market is still massively underestimating what the growth is going to look like for the AI revolution in tech," he told CNBC. Trending: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — According to him, tech trade remains significant even for the investors who missed out on its growth in the past few years. "If you focus just on valuation, you miss every transformational tech stock of the last 20 years," Ives said. Ives says Oracle Corp. (NYSE:ORCL) will be the 'epicenter' of the AI theme, while highlighting other 'AI 30' stocks which are part of his fund. Palantir Technologies Inc. (NASDAQ:PLTR), International Business Machines Corp. (NYSE:IBM), Salesforce Inc. (NYSE:CRM), SoundHound AI Inc. (NASDAQ:SOUN), and Innodata Inc. (NASDAQ:INOD) are a few notable names that are a part of his ETF's 'AI 30' basket. Microsoft Corp. (NASDAQ:MSFT), Nvidia Corp. (NASDAQ:NVDA), and Broadcom Inc. (NASDAQ:AVGO) are the top three holdings of the IVES It Matters: The 'AI 30' stocks, which are a part of the IVES ETF, hold the AI plays from multiple industries. They include hyperscalers, cybersecurity, consumer platforms, and robotics. According to Ives, the list was compiled from his deep dives into major AI players. The ETF has $183 million in assets under management as of June 17 close. Ives said that the AI space was experiencing a "golden age." The Dan IVES Wedbush AI Revolution ETF has risen by 2.76% since its inception. A comparable index, S&P Kensho Global Artificial Intelligence Enablers, rose 6.08% on a month-to-date basis. Meanwhile, the SPDR S&P 500 ETF Trust (NYSE:SPY) and Invesco QQQ Trust ETF (NASDAQ:QQQ), which track the S&P 500 index and Nasdaq 100 index, respectively, declined slightly on Wednesday. The SPY was down 0.015% at $597.44, while the QQQ was 0.017% lower at $528.99, according to Benzinga Pro data. Read Next: Invest early in CancerVax's breakthrough tech aiming to disrupt a $231B market. Back a bold new approach to cancer treatment with high-growth potential. If there was a new fund backed by Jeff Bezos offering a 7-9% target yield with monthly dividends would you invest in it? Photo courtesy: Shutterstock This article Dan Ives Says Market Is 'Massively Underestimating' This AI Play, Urges Investors To Look Beyong Mag 7 originally appeared on
Yahoo
44 minutes ago
- Yahoo
Christina Bohannan makes third run for Iowa's 1st Congressional District
Jun. 21—History shows that just because a candidate makes multiple attempts to win an election doesn't mean they can't eventually pull through. U.S. Rep. Mariannette Miller-Meeks lost a number of times to Dave Loebsack before winning Iowa's 1st Congressional District seat in a close 2020 election. Now her past Democratic challenger, Christina Bohannan, is attempting the same thing for the 2026 election cycle, provided she is the favorite in the primary. On June 17, Bohannan announced her campaign to take on Miller-Meeks once again. In a press release, her campaign said Bohannan nearly defeated Miller-Meeks in 2024 — less than 800 votes decided the election — and that the Democrat "outworked, outraised and outmatched her." Bohannan said, "Mariannette Miller-Meeks has had three terms in Congress — three chances to do right by the people of Iowa. Instead, she has taken over $4 million from corporate special interests and done nothing but vote their way. And she has put partisan politics over Iowans again and again. From cutting billions of dollars from Medicaid in the Trump Administration's One Big Beautiful Bill, to siding with DOGE's cuts to Social Security and enabling unelected, unaccountable billionaires like Elon Musk, Bohannan said the Republican congresswoman has forgotten about her constituents. "It's time someone put Iowa first," Bohannan said. Bohannan went on to say Miller-Meeks needs to explain "why she keeps putting Washington special interests first." The Democratic challenger claimed Miller-Meeks supported Trump's One Big Beautiful Bill, repeatedly voted for cost-increasing tariffs and is a member of the DOGE Caucus. Bohannan previously worked as an engineer and taught at the University of Iowa College of Law for 20 years. She also worked as an elected legislator for the Iowa House, defeating a 20-year incumbent in District 85. Bohannan is running for Congress because she believes in a government that works for the people. In May, another Democrat announced he would be running for Iowa's 1st Congressional District. Bob Krause, a former legislator who also tried running for U.S. Senate, announced his campaign with the slogan "Flip The House With Krause." Krause said Miller-Meeks votes "like Trump's rubber stamp." Travis Terrell, a Democrat from Johnson County, also announced his bid for Iowa's 1st Congressional District race. His campaign page on Facebook notes he is a working-class, New Deal Democrat fighting for healthcare, fair wages and a government that serves other working-class people and not billionaires. In addition to Miller-Meeks likely running for the seat, fellow Republican and former primary challenger David Pautsch announced in February that he would also be running for the seat. Pautsch touts himself as a MAGA Republican. He has been critical of Miller-Meeks, saying she is not conservative enough.
